NCT00866047 · OUTCOME

Maximum Serum Concentration

A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma · Source last updated 2017-03-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

What was measured

Maximum serum concentration from 0 to 21 days following the first dose of brentuximab vedotin

Analysis population: All participants who received treatment

Brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Brentuximab Vedotin	58

Source class 1

Values in microgram/mL · Interval/dispersion: Geometric Coefficient of Variation
Group	Value	Spread	Lower	Upper	Comment
Brentuximab Vedotin	37	20	Not reported	Not reported	Not reported

Complete source fields

classes

denoms

description

Maximum serum concentration from 0 to 21 days following the first dose of brentuximab vedotin

dispersion Type

Geometric Coefficient of Variation

groups

param Type

GEOMETRIC_MEAN

population Description

All participants who received treatment

reporting Status

POSTED

time Frame

3 weeks

title

Maximum Serum Concentration

type

SECONDARY

unit Of Measure

microgram/mL

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Independent clinical review pending · Not medical advice